Is Exact Sciences Corporation (EXAS) a Buy? The Stock Reaches 52-Week High Today

June 13, 2018 - By Hannah Black

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Investors sentiment increased to 1.15 in Q1 2018. Its up 0.27, from 0.88 in 2017Q4. It is positive, as 43 investors sold Exact Sciences Corporation shares while 80 reduced holdings. 54 funds opened positions while 88 raised stakes. 101.92 million shares or 10.20% more from 92.48 million shares in 2017Q4 were reported.
Gideon Cap Advsrs has invested 0.38% in Exact Sciences Corporation (NASDAQ:EXAS). Zevenbergen Cap Invests Ltd Liability Co holds 2.03 million shares or 3.15% of its portfolio. Smith Asset Mgmt Gp Ltd Partnership invested 0.02% in Exact Sciences Corporation (NASDAQ:EXAS). State Street reported 3.73M shares. Nuveen Asset Management owns 33,671 shares or 0.01% of their US portfolio. California State Teachers Retirement owns 179,148 shares for 0.02% of their portfolio. Tiverton Asset Mngmt Limited Company holds 0.62% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 222,818 shares. Alliancebernstein L P stated it has 2.68 million shares. Stratos Wealth Prtnrs Ltd has 413 shares. Point72 Asset Limited Partnership holds 576,800 shares. Axiom Invsts Limited Liability Corp De has invested 0.04% in Exact Sciences Corporation (NASDAQ:EXAS). Us Fincl Bank De has invested 0.09% in Exact Sciences Corporation (NASDAQ:EXAS). Antipodean Advsr Ltd Co owns 236,346 shares or 10.54% of their US portfolio. Nordea Inv Mngmt invested in 62,019 shares or 0.01% of the stock. Brick & Kyle Associate holds 0.25% or 7,550 shares in its portfolio.

Since January 2, 2018, it had 0 buys, and 21 selling transactions for $25.11 million activity. $6.62M worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by Conroy Kevin T. COWARD D SCOTT also sold $141,341 worth of Exact Sciences Corporation (NASDAQ:EXAS) on Friday, March 9. ARORA MANEESH sold $243,068 worth of stock or 5,512 shares. 7,402 shares valued at $381,447 were sold by WYZGA MICHAEL S on Thursday, May 10. Elliott Jeffrey Thomas had sold 2,982 shares worth $126,252. LIDGARD GRAHAM PETER sold $1.11M worth of stock.

The stock of Exact Sciences Corporation (NASDAQ:EXAS) hit a new 52-week high and has $73.17 target or 6.00 % above today’s $69.03 share price. The 9 months bullish chart indicates low risk for the $8.42B company. The 1-year high was reported on Jun, 13 by Barchart.com. If the $73.17 price target is reached, the company will be worth $504.90M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 3.46% or $2.31 during the last trading session, reaching $69.03. About 794,061 shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 56.13% since June 13, 2017 and is uptrending. It has outperformed by 43.56% the S&P500.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on July, 24. They expect $-0.33 EPS, down 22.22 % or $0.06 from last year’s $-0.27 per share. After $-0.33 actual EPS reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 11 analysts covering Exact Sciences (NASDAQ:EXAS), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Exact Sciences has $70 highest and $50.0 lowest target. $61.67’s average target is -10.66% below currents $69.03 stock price. Exact Sciences had 19 analyst reports since December 20, 2017 according to SRatingsIntel. The firm has “Hold” rating given on Friday, February 23 by Stephens. The company was maintained on Wednesday, January 17 by Benchmark. The firm has “Buy” rating by William Blair given on Thursday, March 29. Canaccord Genuity maintained the stock with “Buy” rating in Monday, March 19 report. Canaccord Genuity maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Wednesday, June 6. Canaccord Genuity has “Buy” rating and $70 target. The stock has “Buy” rating by Cowen & Co on Wednesday, December 20. Canaccord Genuity maintained it with “Buy” rating and $68 target in Thursday, May 31 report. The firm has “Outperform” rating by Robert W. Baird given on Tuesday, June 5. On Tuesday, April 3 the stock rating was upgraded by BTIG Research to “Buy”. Benchmark downgraded Exact Sciences Corporation (NASDAQ:EXAS) on Friday, February 23 to “Hold” rating.

More recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Seekingalpha.com which released: “Exact Sciences advancing biomarker panel for liver cancer” on June 05, 2018. Also Fool.com published the news titled: “20 Million More Potential Customers for Cologuard: Time to Buy Exact Sciences Stock?” on June 04, 2018. Seekingalpha.com‘s news article titled: “Exact Sciences upsizes and prices of 1.0% convertible senior notes due 2025” with publication date: June 08, 2018 was also an interesting one.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $8.42 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: